As Palantir Technologies prepares to report Q4 results, options markets signal significant volatility ahead, with the stock's AI-driven rally facing a reality check amid shifting investor focus.
Apple's record-breaking quarter highlighted a persistent memory chip shortage, driven by AI demand. This dynamic is creating a powerful tailwind for U.S.-based memory leader Micron Technology, with industry commentary suggesting the upcycle has further to run.
ARK Invest CEO Cathie Wood argues the parabolic rise in gold, not artificial intelligence, represents the current asset bubble, pointing to its recent sharp correction as validation of her view while reaffirming her bullish stance on Bitcoin.
Analyst firm Argus has raised its price target for Sanmina Corporation (SANM) to $200, maintaining a Buy rating following the company's better-than-expected Q1 2026 results and robust positioning in key growth markets.
Dolby Laboratories surpassed Wall Street's Q4 revenue and profit forecasts, fueled by strong growth in automotive partnerships and streaming adoption. However, a year-over-year sales decline and contracting operating margins highlight the challenges of shifting product mix and restructuring costs.
TAL Education Group's stock soared following robust Q3 FY2026 results and a new share repurchase program, marking a potential inflection point for the Chinese tutoring giant navigating a post-regulatory landscape. Analysts debate if the rally signals a lasting recovery or a temporary reprieve.
International Flavors & Fragrances (IFF) shares have lagged the broader market, raising questions about its turnaround strategy and long-term value proposition for investors.
Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.
A.O. Smith's Q4 2025 earnings reveal a tale of two stories: revenue that missed expectations but profits that beat them. The water technology leader is leaning into commercial strength and operational discipline to expand margins, even as it braces for a challenging 2026 marked by input cost inflation and persistent softness in its China business.
Brunswick Corporation surpassed Q4 revenue and profit expectations, buoyed by stabilizing retail demand. However, a cautious near-term forecast and persistent tariff headwinds cloud its 2026 trajectory, highlighting the complex currents facing the marine industry.
Mastercard's Q4 2025 results surpassed profit expectations, driven by strong demand for its value-added services and key global partnerships, highlighting the payments giant's resilience amid economic uncertainty.
Ahead of its Q4 2025 results, Citigroup has revised its price target for PDD Holdings downward, maintaining a Neutral stance. The adjustment reflects concerns over slowing Chinese consumer spending and rising operational costs for its international platform, Temu.
Chinese tutoring giant TAL Education Group surpassed revenue and profit expectations for its fiscal third quarter, reporting net income of $130.6 million. The results signal a successful strategic pivot following China's sweeping education sector reforms.
Carnival Corporation & plc sees its shares rally after posting a record $4.5 billion in operating income for fiscal 2025, reinstating a quarterly dividend, and announcing plans to consolidate its dual-listed structure into a single NYSE entity, signaling a renewed focus on shareholder returns and corporate simplicity.
Despite posting quarterly results that beat analyst expectations, KLA Corporation's stock plunged Friday as investors focused on management warnings about component shortages, tariff impacts, and operational constraints.
John B. Sanfilippo & Son posts record revenue and a 32% jump in EPS for fiscal Q2 2026, even as higher nut costs and shifting consumer habits pressure sales volumes. The snack nut processor eyes future growth through operational efficiency and new bar production capacity.
Shares of Corcept Therapeutics plunged 16% after a corrected FDA letter disclosed the agency had repeatedly cautioned the company against filing its application for a Cushing's syndrome drug, which was later rejected over efficacy and safety concerns.
Financial Institutions Inc. (FISI) reported solid Q4 and full-year 2025 results, with net income reaching $73.4 million. The community bank, leveraging its deep roots in Upstate New York, is positioning for further growth in 2026, buoyed by major local investments like Micron's semiconductor project.
Financial Institutions (FISI) reported solid Q4 and full-year 2025 results, beating guidance on key profitability metrics. Management highlighted disciplined loan growth, a strengthened capital position, and strategic shifts, while pointing to long-term opportunities from major industrial investments in its Upstate New York footprint.
Iran's foreign minister stated readiness for 'fair' negotiations with Washington but firmly ruled out discussing its defense capabilities, as regional powers intensify diplomacy to avert a military confrontation.
